

> Diseases with mechanical and/or electrical dysfunction of the myocardium


# CARDIOMYOPATHIES

_Diseases with mechanical and/or electrical dysfunction of the myocardium_

### DILATED CARDIOMYOPATHY (DCM)

### 定義 and 流行病學 (_Circ_ 2013;128:e240; _JACC_ 2013;62:2046)

• Ventricular dilatation and ↓ contractility ± ↓ wall thickness _in the absence of myocardial disease caused by ischemia/infarct, valvular disease or hypertension_

• Incidence: 5–8/100,000/y; prevalence: 1/2500. Most common reason for heart transplant.

### 原因 (_JACC_ 2011;57:1641; _Circ Res_ 2012;111:131)

• **Familial** (~35%): Pt & ≥2 closely related family members with otherwise unexplained DCM; ~30 genes identified to date, encoding structural & nuclear proteins

• **Idiopathic** (<20%): ? undiagnosed infectious, alcoholic, or genetic cause

• **Infectious myocarditis** (10–15%; _Lancet_ 2012;379:738; _JACC_ 2012;59:779)

Viruses (parvoB19 & HHV6 > Coxsackie, adeno, echo, CMV, HCV): from subacute (dilated LV, mild–mod dysfxn) to fulminant (nondil., thick, edematous LV, sev dysfxn)

Bacterial, fungal, rickettsial, TB, Lyme (mild myocarditis, often with AVB)

HIV: ~8% of asx HIV ⊕; due to HIV, other virus _or_ antiretrovirals; also premature CAD

Chagas: apical aneurysm ± thrombus, RBBB, megaesophagus/colon (_Lancet_ 2018;391:82)

• **Toxic:** alcohol (~20%) typ. 7–8 drinks/d × >5 y, but variable; cocaine; XRT (usu RCMP);

anthracyclines (risk ↑ >550 mg/m2, may manifest late), cyclophosphamide, trastuzumab

• **Infiltrative** (5%): often mix of DCMP + RCMP (qv) with thickened wall

amyloidosis, sarcoidosis, hemochromatosis, tumor

• **Autoimmune:** _collagen vasc. dis._ (3%): PM, SLE, scleroderma, PAN, RA, GPA;

_peripartum_ (last month → 5 mo postpartum; _EHJ_ 2015;36:1090): ~1:3000 preg. ↑ risk with multiparity, ↑ age, Afr Am; stnd HF Rx (if preg, no ACEi or spironolact.); ? bromocriptine to ↓ prolactin; 72% normalize EF (_JACC_ 2015;66:905); ~30% recur with next preg

Idiopathic giant cell myocarditis (GCM): avg age 42, fulminant, AVB/VT (_Circ HF_ 2013;6:15)

Eosinophilic (variable peripheral eos): hypersensitivity (mild HF but at risk for SCD) or acute necrotizing eosinophilic myocarditis (ANEM; STE, effusion, severe HF)

• **Stress-induced** (Takotsubo = apical ballooning): typically postmenopausal ♀; mimics MI (chest pain, ± STE & ↑ Tn; deep TWI & ↑ QT); mid/apex dyskinesis; ? Rx with βB, ACEI; usu. improves over wks (_JAMA_ 2011;306:277). In-hosp morb/mort similar to ACS (_NEJM_ 2015;373:929).

• **Arrhythmogenic right ventricular cardiomyopathy** (ACM/ARVC): fibrofatty replacement of RV → dilation (dx with MRI); ECG: ± RBBB, TWI V1–V3, ε wave; risk VT (_NEJM_ 2017;376:61)

• **Tachycardia:** likelihood ∝ rate/duration; often resolves with rate cntl (_Circ_ 2005;112:1092)

• **LV noncompaction** (_Lancet_ 2015;386:813): prominent trabeculae, arrhythmias, cardioemboli

• **Metab/other:** hypothyroid, acromegaly, pheo, OSA, Vit B1, selenium or carnitine defic.

### 臨床表現

• **Heart failure:** both congestive & poor forward flow sx; signs of L- & R-sided HF

### diffuse, **laterally displaced PMI**, **S3**, ± MR or TR (annular dilat., displaced pap. muscle)

• Embolic events (~10%), supraventricular/ventricular arrhythmias, & palpitations

• Chest pain can be seen with some 原因 (eg, myocarditis)

### Diagnostic studies and workup (_JACC_ 2016;67:2996)

• CXR: moderate to marked cardiomegaly, ± pulmonary edema & pleural effusions

• ECG: may see PRWP, Q waves, or BBB; low-voltage; AF (20%); may be normal

• Echocardiogram: LV dilatation, ↓ EF, _regional or global_ LV HK ± RV HK, ± mural thrombi

• Cardiac MRI: up to 76% Se, 96% Sp for myocarditis or infiltrative dis. (_JACC Imaging_ 2014;7:254); extent of midwall fibrosis correlated with mortality in niCMP (_JAMA_ 2013;309:896) and may identify 病人 with EF >40% who benefit from ICD (_Circ_ 2017;135:2106)

• Labs: TFTs, Fe panel, HIV, SPEP, ANA; viral sero _not_ recommended; others per suspicion

• Family hx (20–35% with familial dis.), genetic counseling ± genetic testing (_JAMA_ 2009;302:2471)

• Stress test: useful to 排除 ischemia (low false ⊖ rate), high false ⊕ rate, even with imaging

• Coronary angiography to 排除 CAD if risk factors, h/o angina, Qw MI on ECG, equivocal ETT; consider CT angiography (_JACC_ 2007;49:2044)

• ? Endomyocardial biopsy (_JACC_ 2007;50:1914): yield 10%; of these, 75% myocarditis (for which no proven Rx) & 25% systemic disease; 40% false ⊖ rate (patchy dis.) & false ⊕ (necrosis → inflammation); ∴ biopsy if: acute & hemodyn compromise (排除 GCM, ANEM); arrhythmia or RCMP features (排除 infiltrative); or suspect toxic, allergic, tumor

### 治療 (see “Heart Failure” for standard HF Rx)

• Possibility of reversibility of CMP may temper implantation of devices

• Immunosuppression: for giant cell myocarditis (prednisone + AZA), collagen vascular disease, peripartum (? IVIg), & eosinophilic; no proven benefit for viral myocarditis

• Prognosis differs by etiology (_NEJM_ 2000;342:1077): postpartum (best), ischemic/GCM (worst)

### HYPERTROPHIC CARDIOMYOPATHY (HCM)

### 定義 and 流行病學

• LV (usually ≥15 mm) and/or RV hypertrophy disproportionate to hemodynamic load

• Prevalence: 1/500; 50% sporadic, 50% familial, most asymptomatic

• Ddx: LVH 2° to HTN, AS, elite athletes (wall usually <13 mm & symmetric and 正常/↑ rates of tissue Doppler diastolic relaxation; _Circ_ 2011;123:2723), Fabry dis. (↑ Cr, skin findings)

### Pathology

• Autosomal dominant mutations in cardiac sarcomere genes (eg, β-myosin heavy chain)

• Myocardial fiber disarray with hypertrophy, which creates arrhythmogenic substrate

• Many morphologic hypertrophy variants: asymmetric septal; concentric; midcavity; apical

### 病生理

• LV outflow tract obstruction (LVOTO) in ≥70%: narrowed tract 2° hypertrophied septum + systolic anterior motion (SAM) of ant. MV leaflet (may be fixed, variable, or nonexistent) and papillary muscle displacement. Gradient (∇) worse with ↑ contractility (digoxin, β-agonists, exercise, PVCs), ↓ preload (eg, Valsalva maneuver) or ↓ afterload.

• Mitral regurgitation: due to SAM (mid-to-late, post.-directed regurg. jet) and/or 異常

mitral leaflets and papillary muscles (pansystolic, ant.-directed regurg. jet)

• Diastolic dysfunction: ↑ chamber stiffness + impaired relaxation

• Ischemia: small vessel dis., perforating artery compression (bridging), ↓ coronary perfusion

• Syncope: ∆s in load-dependent CO, arrhythmias

### 臨床表現 (70% are asymptomatic at dx)

• **Dyspnea** (90%): due to ↑ LVEDP, MR, and diastolic dysfunction

• **Angina** (25%) even without epicardial CAD; microvasc. dysfxn (_NEJM_ 2003;349:1027)

• **Arrhythmias** (AF in 20–25%; VT/VF): palpitations, syncope, sudden cardiac death

### Physical exam

• Sustained PMI, S2 paradoxically split if severe outflow obstruction, ⊕ S4 (occ. palpable)

• **Systolic murmur:** crescendo-decrescendo; LLSB; ↑ **w/ Valsalva** & standing (↓ preload)

• ± mid-to-late or holosystolic murmur of MR at apex

• Bifid carotid pulse (brisk rise, decline, then 2nd rise); JVP with prominent _a_ wave

• Contrast to AS, which has murmur that ↓ with Valsalva and ↓ carotid pulses

### Diagnostic studies (_EHJ_ 2014;35:2733)

• CXR: cardiomegaly (LV and LA)

• ECG: LVH, anterolateral TWI and inferior pseudo-Qw, ± apical giant TWI (apical variant)

• **Echo:** any LV wall segment ≥15 mm (or ? even ≥13 if ⊕ HFx), often but not necessarily involving septum; other findings include dynamic outflow obstruction, SAM, MR

• MRI: hypertrophy + patchy delayed enhancement (useful for dx & prog) (_Circ_ 2015;132:292)

• Cardiac cath: subaortic pressure ∇; _Brockenbrough sign_ = ↓ pulse pressure post-PVC (in contrast to AS, in which pulse pressure ↑ post-PVC); spike & dome Ao pressure pattern

• ? Genotyping for family screening, but pathogenic mutation ID’d in <1/2 (_Circ_ 2011;124:2761)

### 治療 (_EHJ_ 2014;35:2733; _NEJM_ 2018;379:655)

• Heart failure

⊖ **inotropes/chronotropes:** β-blockers, CCB (verapamil), disopyramide

Careful use of diuretics, because may further ↓ preload. If LVOTO, _avoid vasodilators_. Avoid digoxin b/c ↑ contractility and ∴ outflow obstruction.

If sx refractory to drug Rx + _obstructive_ physiology (∇ ≥50 mmHg):

(a) Surgical myectomy: long-term ↓ symptoms in 90% (_Circ_ 2014;130:1617)

(b) Alcohol septal ablation (_JACC_ 2018;72:3095): ∇ ↓ by ~80%, only 5–20% remain with NYHA III–IV sx; 14% require repeat ablation or myectomy. Good alternative for older 病人, multiple comorbidities. Complic: transient (& occ. delayed) 3° AVB with 10–20% req. PPM; VT due to scar formation.

No clear benefit of dual-chamber pacing (_JACC_ 1997;29:435; _Circ_ 1999;99:2927)

If refractory to drug therapy and there is _nonobstructive_ 病生理: transplant

• Acute HF: can be precip. by dehydration or tachycardia; Rx with fluids, βB, phenylephrine

• AF: rate control with βB, maintain SR with disopyramide or amio; low threshold to anticoag

• ICD if VT/VF. Consider for SCD prevention if: NSVT, ⊕ FHx SCD, unexplained syncope, LV wall ≥30 mm, failure of SBP to ↑ or fall from peak ≥20 mmHg with exercise, ? extensive MRI delayed enhancement. EPS _not_ useful. HCM Risk-SCD Score (_EHJ_ 2014;35:2010): consider ICD if high risk (≥6%/y), may consider if intermediate (4–<6%/y).

• Counsel to avoid dehydration, extreme exertion

• Endocarditis prophylaxis not recommended (_Circ_ 2007;16:1736)

• 1st\-degree relatives: screen with TTE q12–18m as teen or athlete then q5y as adult, ECG (because timing of HCMP onset variable). Genetic testing if known mutation.

### RESTRICTIVE CARDIOMYOPATHY (RCM)

### 定義 (_Circ_ 2006;113:1807)

• Impaired ventricular filling with ↓ compliance in nonhypertrophied, nondilated ventricles; normal or ↓ diastolic volumes, normal or near-normal EF; must 排除 pericardial disease

### Etiology (_JACC_ 2010;55:1769 & 2016;68:411)

• **Myocardial processes**

Autoimmune (scleroderma, polymyositis-dermatomyositis)

Infiltrative diseases (see primary entries for extracardiac 表現, Dx, Rx)

### Amyloidosis (_Circ_ 2011;124:1079): age at presentation ~60 y; ♂:♀ = 3:2

AL (eg, MM, etc.); familial (transthyretin, ATTR); AA/senile (dep. of TTR, ANP)

ECG: ↓ QRS amplitude (50%), pseudoinfarction pattern (Qw), AVB (10–20%), hemiblock (20%), BBB (5–20%)

Echo: biventricular wall thickening (_yet with low voltage on ECG_), granular sparkling (30%), biatrial enlargement (40%), valve thickening, small effusions

Nl voltage/septal thickness has NPV ~90%

Labs: ✔ SPEP/UPEP, serum free light chain ratio (<0.25 or >1.65 κ-to-λ ratio)

MRI: distinct late gadolinium enhancement pattern (_JACC_ 2008;51:1022)

### Sarcoidosis (can also be DCM): presents at age ~30 y; ↑‘d in blacks, N. Europe, ♀

5% with systemic sarcoid have overt cardiac involvement; cardiac without systemic in 10%

ECG: AVB (75%), RBBB (20–60%), VT; PET: ↑ FDG uptake in affected area

Echo: regional WMA (particularly basal septum) with thinning or mild hypertrophy

Gallium or FDG uptake at areas of inflam.; sestaMIBI with non-cor. perfusion defects

Cardiac MRI: T2 early gad (edema); fibrosis/scar in basal septum; LGE prognostic

Cardiac bx low-yield b/c patchy

**Hemochromatosis:** in middle-aged men (espec N. European); 15% 表現為 cardiac sx

Diabetes; storage diseases: Gaucher’s, Fabry, Hurler’s, glycogen storage diseases

• **Endomyocardial processes**

Chronic eosinophilic: Löffler’s endocarditis (temperate climates; ↑ eos; mural thrombi that embolize); endomyocardial fibrosis (tropical climates; var. eos; mural thrombi)

Toxins: radiation (also 表現為 constrictive pericarditis, valvular dis, ostial CAD), anthracyclines

Serotonin: carcinoid, serotonin agonists, ergot alkaloids. Metastatic cancer.

### Pathology & 病生理

• Path: normal or ↑ wall thickness ± infiltration or abnormal deposition

• ↓ myocardial compliance → 正常 EDV but ↑ EDP → ↑ systemic & pulm. venous pressures

• ↓ ventricular cavity size → ↓ SV and ↓ CO

### 臨床表現 (_Circ_ 2000;101:2490)

• **Right-sided** > **left-sided heart failure** with peripheral edema > pulmonary edema

• **Diuretic “refractoriness”; thromboembolic events**

• Poorly tolerated tachyarrhythmias; VT → syncope/sudden cardiac death

### Physical exam

• ↑ JVP, ± Kussmaul’s sign (JVP not ↓ with inspir., classically seen in _constrict. pericarditis_)

• Cardiac: ± S3 and S4, ± murmurs of MR and TR

• Congestive hepatomegaly, ± ascites and jaundice, peripheral edema

### Diagnostic studies

• CXR: normal ventricular chamber size, enlarged atria, ± pulmonary congestion

• ECG: low voltage, pseudoinfarction pattern (Qw), ± arrhythmias

• Echo: ± symmetric wall thickening, biatrial enlarge., ± mural thrombi, ± cavity oblit. with diast dysfxn: ↑ early diast (E) and ↓ late atrial (A) filling, ↑ E/A ratio, ↓ decel. time

• Cardiac MRI/PET: may reveal inflammation or evidence of infiltration (but nonspecific)

• Cardiac catheterization

Atria: **M’s** or **W’s** (prominent _x_ and _y_ descents)

Ventricles: **dip & plateau** (rapid ↓ pressure at onset of diastole, rapid ↑ to early plateau)

### Concordance of LV & RV pressure peaks during respiratory cycle (vs. discordance in constrictive pericarditis; _Circ_ 1996;93:2007)

• Endomyocardial biopsy if suspect infiltrative process; fat pad bx for amyloid

• Restrictive cardiomyopathy vs. constrictive pericarditis: see “Pericardial Disease”

### 治療 (in addition to Rx’ing underlying disease)

• Gentle diuresis. May not tolerate CCB or other vasodilators.

• Control HR (but can ↓ CO); maintain SR (helps filling). Digoxin ↑ arrhythmias in amyloid.

• Anticoagulation (particularly with AF or low CO)

• Transplantation for refractory cases

• Tafamidis (TTR binder) ↓ death and CV hosp for TTR amyloid CM (_NEJM_ 2018;379:1007)
